1330 related articles for article (PubMed ID: 16521130)
1. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
2. Pre-transplant minimal residual disease in children with acute lymphoblastic leukemia.
Mehta PA; Davies SM
Pediatr Blood Cancer; 2007 Jan; 48(1):1-2. PubMed ID: 16642487
[No Abstract] [Full Text] [Related]
3. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
4. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
[TBL] [Abstract][Full Text] [Related]
5. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
6. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.
Bader P; Hancock J; Kreyenberg H; Goulden NJ; Niethammer D; Oakhill A; Steward CG; Handgretinger R; Beck JF; Klingebiel T
Leukemia; 2002 Sep; 16(9):1668-72. PubMed ID: 12200679
[TBL] [Abstract][Full Text] [Related]
9. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan.
Imashuku S; Terui K; Matsuyama T; Asami K; Tsuchiya S; Ishii E; Kawa K; Kosaka Y; Eguchi H; Tsuchida M; Ikuta K; Kato S; Koizumi S; Okamura J; Morimoto A; Hibi S; Hamaoka K;
Bone Marrow Transplant; 2003 Jun; 31(12):1127-35. PubMed ID: 12796792
[TBL] [Abstract][Full Text] [Related]
10. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
11. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
[TBL] [Abstract][Full Text] [Related]
12. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy?
Bader P; Kreyenberg H; Hoelle W; Dueckers G; Handgretinger R; Lang P; Kremens B; Dilloo D; Sykora KW; Schrappe M; Niemeyer C; Von Stackelberg A; Gruhn B; Henze G; Greil J; Niethammer D; Dietz K; Beck JF; Klingebiel T
J Clin Oncol; 2004 May; 22(9):1696-705. PubMed ID: 15117992
[TBL] [Abstract][Full Text] [Related]
13. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
14. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
Miglino M; Berisso G; Grasso R; Canepa L; Clavio M; Pierri I; Pietrasanta D; Gatto S; Varaldo R; Ballerini F; Verdiani S; Casarino L; DeStefano F; Sessarego M; Dominietto A; Raiola AM; Bregante S; di Grazia C; Gobbi M; Bacigalupo A
Bone Marrow Transplant; 2002 Nov; 30(9):579-85. PubMed ID: 12407432
[TBL] [Abstract][Full Text] [Related]
16. Assessment of clonal stability of minimal residual disease targets between 1st and 2nd relapse of childhood precursor B-cell acute lymphoblastic leukemia.
Guggemos A; Eckert C; Szczepanski T; Hanel C; Taube T; van der Velden VH; Graf-Einsiedel H; Henze G; Seeger K
Haematologica; 2003 Jul; 88(7):737-46. PubMed ID: 12857551
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
[TBL] [Abstract][Full Text] [Related]
18. Applicability of IG/TCR gene rearrangements as targets for minimal residual disease assessment in a population-based cohort of Swedish childhood acute lymphoblastic leukaemia diagnosed 2002-2006.
Thörn I; Forestier E; Thuresson B; Wasslavik C; Malec M; Li A; Lindström-Eriksson E; Botling J; Barbany G; Jacobsson S; Olofsson T; Porwit A; Sundström C; Rosenquist R
Eur J Haematol; 2010 Feb; 84(2):117-27. PubMed ID: 19895569
[TBL] [Abstract][Full Text] [Related]
19. A demographic study of the clinical significance of minimal residual disease in children with acute lymphoblastic leukemia.
Levett D; Middleton P; Cole M; Reid MM
Med Pediatr Oncol; 2001 Mar; 36(3):365-71. PubMed ID: 11241438
[TBL] [Abstract][Full Text] [Related]
20. Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia.
Candoni A; Tiribelli M; Toffoletti E; Cilloni D; Chiarvesio A; Michelutti A; Simeone E; Pipan C; Saglio G; Fanin R
Eur J Haematol; 2009 Jan; 82(1):61-8. PubMed ID: 18801058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
